- 7. Select an appropriate size 0.9% Sodium Chloride Injection infusion bag and prepare by removing a volume equal to the required FABRAZYME volume to achieve a total volume per Table 1.
- 8. Slowly withdraw the required volume of reconstituted solution from the FABRAZYME vial(s). Discard any unused reconstituted solution remaining in the vial.
Table 1: Total Infusion Volume Based on Patient Weight| Patient Weight (kg) | Total Volume (mL) |
|---|
| ≤35 | 50 |
| 35.1 to 70 | 100 |
| 70.1 to 100 | 250 |
| >100 | 500 |
- 9. Gently inject the FABRAZYME reconstituted solution into the port of the 0.9% Sodium Chloride Injection infusion bag. Do not inject into the airspace within the infusion bag.
- 10. Gently invert the infusion bag to mix the solution. Do not shake or agitate the product. After dilution, the solution will have a final concentration of 0.2 to 0.7 mg/mL of agalsidase beta.
Most Common Adverse Reactions
Table 2 enumerates adverse reactions that occurred during the double-blind treatment periods of the two placebo-controlled trials (Study 1 and Study 2) [see Clinical Studies (14)]. The most common adverse reactions reported with FABRAZYME were infusion-associated reactions, (FABRAZYME 59% vs placebo 27%) some of which were severe (FABRAZYME 5.0% vs placebo 1.7%). Infusion-associated reactions are defined as adverse reactions occurring on the same day as the infusion.
Common adverse reactions which occurred in ≥20% of patients treated with FABRAZYME and >2.5% compared to placebo are: upper respiratory tract infection, chills, pyrexia, headache, cough, paresthesia, fatigue, peripheral edema, dizziness and rash.
Table 2: Summary of Common Adverse ReactionsReported at rate of at least 5% in FABRAZYME-treated patients and greater than 2.5% compared to placebo-treated patients.
in Clinical Trials (Study 1 and 2) of Patients with Fabry Disease| Adverse Reaction | FABRAZYME (n=80) % | Placebo (n=60) % |
|---|
| Upper respiratory tract infection Includes reports of upper respiratory infection, nasal congestion, sinusitis, respiratory tract congestion, and pharyngitis. | 53 | 42 |
| Chills Includes reports of chills and feeling cold. | 49 | 13 |
| Pyrexia | 39 | 22 |
| Headache | 39 | 28 |
| Cough | 33 | 25 |
| Paresthesia | 31 | 18 |
| Fatigue | 24 | 17 |
| Peripheral edema | 21 | 7 |
| Dizziness | 21 | 8 |
| Rash | 20 | 10 |
| Pain in extremity | 19 | 8 |
| Myalgia Includes reports of myalgia and muscle spasms. | 18 | 7 |
| Lower respiratory tract infection | 18 | 7 |
| Pain | 16 | 13 |
| Back pain | 16 | 10 |
| Hypertension | 14 | 5 |
| Pruritus | 10 | 3 |
| Tachycardia | 9 | 3 |
| Excoriation | 9 | 2 |
| Increased blood creatinine | 9 | 5 |
| Tinnitus | 8 | 3 |
| Dyspnea | 8 | 2 |
| Fall | 6 | 3 |
| Burning sensation | 6 | 0 |
| Anxiety | 6 | 3 |
| Depression | 6 | 2 |
| Wheezing | 6 | 0 |
| Hypoacusis | 5 | 0 |
| Chest discomfort | 5 | 2 |
| Fungal infection | 5 | 0 |
| Viral infection | 5 | 0 |
| Hot flush | 5 | 0 |
Most infusion-associated reactions requiring intervention were ameliorated with slowing of the infusion rate, temporarily stopping the infusion, and/or administration of antipyretics, antihistamines, or steroids.
Adverse Reactions in Pediatric Patients
In Study 3, the safety profile of FABRAZYME in pediatric Fabry disease patients, ages 8 to 16 years, was similar to that seen in adults. The most common adverse reactions (>20%) were headache, abdominal pain, pharyngitis, fever, nausea, vomiting, rhinitis, diarrhea, arthralgia, and dizziness [see Use in Specific Populations (8.4) and Clinical Studies (14)].
Risk Summary
Available data from a pregnancy sub-study within the Fabry Disease registry, post-marketing case reports, and case series with FABRAZYME use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes (see Data). Reproduction studies performed in rats at doses up to 68 times the human dose have revealed no evidence of effects on embryo-fetal development (see Data).
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data
Human Data
Available data from a pregnancy sub-study within the Fabry Disease registry, post-marketing case reports, and case series with FABRAZYME use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In the Fabry Disease registry pregnancy sub-study, 33 pregnancies exposed to FABRAZYME prior to or during pregnancy had a known outcome; 5 were reported as exposed in the first trimester.
Animal Data
The effects of agalsidase beta on embryo-fetal development in rats were evaluated at doses of 3, 10, and 30 mg/kg/day (up to 68 times the human dose of 1 mg/kg every 2 weeks on a body surface area basis) during gestation days 7 to 17. Hepatocellular necrosis consistent with accumulation of test article was evident in maternal livers in the 10 and 30 mg/kg/day groups (23 and 68 times the human dose on a body surface area basis). There were no adverse effects of agalsidase beta on embryo-fetal development in rats.
Risk Summary
The available human data detected small amounts of agalsidase beta in human milk. Available data from the clinical study, global pharmacovigilance database, and published scientific literature are insufficient to determine the effects of FABRAZYME on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for FABRAZYME and any potential adverse effects on the breastfed child from FABRAZYME or from the underlying maternal condition.
Hypersensitivity Reactions Including Anaphylaxis and Infusion-Associated Reactions (IARs)
Advise the patient and caregiver that life-threatening hypersensitivity reactions, including anaphylaxis, and IARs may occur with FABRAZYME treatment.
Advise the patient or caregiver that anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration therapy.
Inform the patient and caregiver of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis, and IARs and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1, 5.2)].
FABRAZYME Exposure During Pregnancy or Lactation
Advise a pregnant or lactating woman exposed to FABRAZYME to report FABRAZYME exposure to her healthcare provider and by calling 1-800-633-1610, option 1 [see Use in Specific Populations (8.1., 8.2)].
Patient Registry
Inform the patient and/or caregiver that a registry has been established for Fabry patients in order to better understand the variability and progression of Fabry disease in the population as a whole, and in women along with monitoring and evaluating long-term treatment effects of FABRAZYME. Additionally, the registry also monitors the effect of FABRAZYME on pregnant women and their offspring. Encourage the patient and/or caregiver to contact the registry program by visiting www. registrynxt.com or by calling 1-800-745-4447, extension 15500.
Manufactured by:
Genzyme Corporation
450 Water Street
Cambridge, MA 02141
A SANOFI COMPANY
U.S. License Number: 1596
FABRAZYME and Genzyme are registered trademarks of Genzyme Corporation